Hepatitis C: Symptoms, Testing, and Treatment

Hepatitis C is a viral liver infection caused by the hepatitis C virus (HCV) — and unlike most chronic diseases, it now has a cure. Direct-acting antiviral (DAA) therapies introduced since 2014 have transformed HCV from a condition that once required years of difficult interferon-based treatment into one that resolves in most patients after 8 to 12 weeks of tablets. Yet despite this therapeutic revolution, an estimated 58 million people worldwide are living with chronic HCV infection, and the majority remain undiagnosed. The challenge with hepatitis C has never been the treatment — it is the silence of the infection itself, which causes no symptoms in most people for decades while slowly damaging the liver.

Understanding hepatitis C — how it is transmitted, who should be tested, and what treatment involves — is essential not just for people with known risk factors, but for anyone who has not been screened. This article explains the biology, natural history, symptoms, diagnosis, and curative treatment of HCV infection in plain language, drawing on current guidelines from the WHO, the American Association for the Study of Liver Diseases (AASLD), and the British Association for the Study of the Liver (BASL).

What Is the Hepatitis C Virus?

HCV is a single-stranded RNA virus belonging to the Flaviviridae family. Unlike hepatitis B, which is a DNA virus that integrates into the host genome, HCV replicates as an RNA virus and does not integrate — meaning it does not create a persistent nuclear reservoir like HBV’s covalently closed circular DNA (cccDNA). This biological difference is central to why HCV is curable with antivirals while HBV functional cure remains elusive: once HCV RNA is eliminated from the body, there is no intrahepatic viral reservoir to drive relapse.

HCV exists in at least six major genotypes (gt1 through gt6) and numerous subtypes, with significant geographic variation in their distribution. Genotype 1 is the most prevalent globally and in North America and Europe, accounting for approximately 46% of infections worldwide. Genotype 3 is common in South and Southeast Asia. Genotype 4 predominates in sub-Saharan Africa and the Middle East. Historically, genotype determined treatment choice because interferon-based regimens had markedly different response rates across genotypes. The development of pangenotypic DAA regimens — treatments effective across all genotypes — has made genotype testing less critical for treatment selection, though it remains useful in certain clinical contexts.

How Hepatitis C Is Transmitted

HCV is a bloodborne virus — it requires direct blood-to-blood contact for transmission. Unlike hepatitis A, it is not transmitted through food or water. Unlike hepatitis B, sexual and perinatal transmission are possible but substantially less efficient. Understanding the actual transmission routes is important because misinformation about HCV transmission contributes significantly to the stigma that deters many people from testing.

Injection drug use accounts for the majority of new HCV infections in high-income countries. Sharing needles, syringes, or other equipment (spoons, filters, water) used to prepare or inject drugs is the most efficient route of transmission. HCV is highly infectious via this route — the virus survives outside the body at room temperature for at least sixteen hours and potentially much longer on contaminated surfaces, making even indirect sharing of equipment a significant risk.

Healthcare-associated transmission was historically a major route and remains important in low and middle-income countries with limited infection control capacity. Blood transfusions and blood products before systematic HCV screening (introduced in the early 1990s in most high-income countries) infected millions globally. Healthcare workers can be exposed through needlestick injuries. Reuse of syringes in some healthcare settings, particularly for injections of medications drawn from multi-dose vials, has caused documented outbreaks. Tattoos and body piercing with non-sterile equipment carry transmission risk.

Sexual transmission of HCV does occur but is substantially less efficient than for HIV or HBV. The risk is low in stable monogamous heterosexual relationships — estimated at less than 1% per year of unprotected sex with an HCV-positive partner. Risk is significantly higher in contexts involving mucosal trauma, co-infection with HIV (which appears to facilitate HCV transmission), or practices involving blood exposure. Men who have sex with men (MSM) — particularly those living with HIV — have experienced epidemic rises in sexually transmitted HCV in many high-income countries.

Perinatal transmission from mother to infant occurs in approximately 5% of pregnancies in HCV-RNA-positive women (rising to around 10% in women co-infected with HIV). There is currently no approved prophylaxis to prevent perinatal HCV transmission, unlike for HBV. DAA treatment during pregnancy is under investigation but not yet approved; the current approach is to treat women before pregnancy when possible, and to test and treat children born to HCV-positive mothers after they are at least eighteen months old (anti-HCV antibody testing is unreliable in children under eighteen months due to maternal antibody transfer).

The Natural History of HCV Infection

After exposure to HCV, there is an incubation period of two to twelve weeks before viremia (detectable HCV RNA in the blood) develops. Most acute HCV infections — around 75 to 85% — progress to chronic infection, defined as HCV RNA detectable for more than six months. The remaining 15 to 25% spontaneously clear the virus, a process mediated by the host immune response; genetic factors, particularly HLA type and variants in the IL28B gene (now known as IFNL3), significantly influence the likelihood of spontaneous clearance.

Chronic HCV infection progresses slowly and silently in the majority of patients. The liver accumulates fibrosis over decades, and the rate of progression varies considerably between individuals depending on age at infection, sex (men progress faster), alcohol use, obesity and metabolic factors, HIV co-infection, and other liver diseases. Population-level studies suggest that after twenty years of chronic HCV infection: approximately 20–30% of patients will have progressed to cirrhosis; 1–4% per year of patients with cirrhosis will develop hepatocellular carcinoma (HCC); and 3–6% per year of cirrhotic patients will experience hepatic decompensation.

Symptoms: Why Most People Don’t Know They Have It

Acute hepatitis C infection is symptomatic in only about 15–20% of cases. When symptoms do occur, they are non-specific: fatigue, nausea, right upper quadrant discomfort, loss of appetite, and occasionally jaundice. The acute infection is rarely identified clinically, and most people who develop chronic HCV do so without any recognised acute illness.

Chronic hepatitis C infection is even more likely to be asymptomatic in its early and middle stages. The liver has substantial reserve capacity, and significant fibrosis — up to and including compensated cirrhosis — can exist without any symptoms that would prompt medical attention. When symptoms do occur in chronic HCV, the most commonly reported are: persistent fatigue (the most common and often the most disabling symptom); cognitive difficulties (“brain fog,” difficulty concentrating); right upper quadrant discomfort; joint and muscle aches; and, in more advanced disease, symptoms of portal hypertension (ascites, ankle swelling, variceal bleeding) or hepatic encephalopathy.

Extrahepatic manifestations of chronic HCV are an underappreciated feature of the disease and can be the first clinical presentation in some patients. HCV has a particular tropism for B lymphocytes and can cause a range of extrahepatic conditions including: mixed cryoglobulinemia (immune complex deposition causing vasculitis, purpura, arthralgia, and glomerulonephritis); B-cell non-Hodgkin lymphoma; lichen planus; porphyria cutanea tarda; thyroid disease (both thyroiditis and hypothyroidism); sicca syndrome; and diabetes mellitus (HCV appears to independently increase insulin resistance and type 2 diabetes risk). Recognition of these extrahepatic conditions is important because they may present to specialists in rheumatology, dermatology, nephrology, or haematology before the underlying HCV is identified.

Who Should Be Tested for Hepatitis C?

Because most HCV infections are asymptomatic, targeted screening based on risk factors alone misses many cases. Current guidelines in several countries, including the US (USPSTF recommendation), recommend one-time HCV testing for all adults aged 18 to 79, regardless of risk factors. The UK’s NHS offers HCV testing through GP practices and sexual health clinics, with targeted programmes for high-risk groups. The WHO recommends HCV testing for all adults in high-prevalence settings.

Groups for whom HCV testing is specifically recommended include:

• People who have ever injected drugs, even once
• Anyone who received a blood transfusion or blood products before 1992 (when systematic screening began in most high-income countries)
• Organ transplant recipients before 1992
• People born to HCV-positive mothers
• People living with HIV
• Men who have sex with men, particularly those living with HIV
• People who have received haemodialysis
• Healthcare workers who have had needlestick injuries involving HCV-positive blood
• People born in countries with HCV prevalence above 2% (including Egypt, Pakistan, China, and many countries in sub-Saharan Africa, Central Asia, and Eastern Europe)
• People who have used intranasal cocaine or other drugs via shared equipment
• People with unexplained chronic liver disease, abnormal liver function tests, or cirrhosis

The HCV Testing Pathway

HCV diagnosis follows a two-step pathway that is important to understand, because a single positive test result does not automatically mean active infection:

Step 1 — Anti-HCV antibody test: The initial screening test detects antibodies that the immune system has produced against HCV. A positive anti-HCV test means the person has been exposed to HCV at some point — but it does not distinguish between active current infection and past infection that has been cleared (either spontaneously or after treatment). Anti-HCV antibodies persist for life even after successful treatment. A negative anti-HCV test in someone with recent potential exposure (within the past three to six months) should be repeated, as antibody seroconversion may not yet have occurred — this is called the window period.

Step 2 — HCV RNA test (nucleic acid amplification test, NAAT): If the anti-HCV antibody test is positive, an HCV RNA test is performed to determine whether the virus is actively present in the blood. A positive HCV RNA test confirms active infection. A negative HCV RNA test in someone with a positive anti-HCV antibody means the infection has been cleared — either spontaneously or following treatment. This distinction matters enormously: a person who has been treated, achieved SVR (cure), and then retested will have a positive anti-HCV antibody for life but a negative HCV RNA — they do not need re-treatment.

Additional testing after confirmed active HCV infection: Genotype testing (to guide treatment selection in non-pangenotypic contexts); baseline liver function tests (ALT, AST, bilirubin, albumin, INR) to assess hepatic inflammation and synthetic function; HCV RNA quantification (viral load); fibrosis assessment — either non-invasive (FibroScan or serum fibrosis markers like FIB-4 score) or liver biopsy in selected cases — to stage liver disease and assess urgency of treatment; HAV and HBV serology (to vaccinate if not immune); and HIV testing.

Staging Liver Disease in HCV: Why It Matters

The degree of liver fibrosis at the time of HCV diagnosis has important implications for treatment urgency, choice of regimen, post-treatment surveillance, and the risk of liver complications even after successful cure. Fibrosis is typically staged on the METAVIR scale: F0 (no fibrosis), F1 (portal fibrosis without septa), F2 (portal fibrosis with few septa), F3 (numerous septa without cirrhosis), F4 (cirrhosis).

Liver biopsy was historically the gold standard for fibrosis staging but is now largely replaced by non-invasive methods in clinical practice. FibroScan (transient elastography) measures liver stiffness in kilopascals (kPa) as a surrogate for fibrosis, with validated cut-offs for each METAVIR stage. Serum fibrosis panels — FIB-4 score (calculated from age, AST, ALT, and platelet count) and APRI (AST-to-platelet ratio index) — are validated non-invasive alternatives that can be calculated from routine blood tests without specialist equipment. These tools allow fibrosis staging without the risks and cost of liver biopsy in most patients.

Patients with F3–F4 fibrosis (advanced fibrosis or cirrhosis) at treatment have specific requirements: longer treatment duration in some regimens (12–16 weeks versus 8 weeks), more intensive monitoring during and after treatment, and ongoing HCC surveillance after SVR because cirrhotic and advanced fibrotic livers retain HCC risk even after viral cure.

Treatment: Direct-Acting Antivirals and the Cure

The introduction of direct-acting antivirals (DAAs) since 2014 represents one of the most dramatic therapeutic advances in the history of hepatology. Where interferon-based regimens once required forty-eight weeks of injections, caused severe side effects (depression, flu-like symptoms, anaemia, neutropenia), and achieved SVR in only 40–80% of patients depending on genotype, modern DAA regimens are oral, taken for 8–12 weeks, cause minimal side effects, and achieve SVR in over 95% of patients across all genotypes. SVR — sustained virological response — is defined as undetectable HCV RNA twelve weeks after completion of treatment, and is widely considered equivalent to cure: relapse after SVR12 is extremely rare.

DAAs target specific steps in the HCV replication cycle. The three main classes are: NS5B polymerase inhibitors (e.g., sofosbuvir — the backbone of most modern regimens); NS5A inhibitors (e.g., velpatasvir, pibrentasvir, ledipasvir — interfere with viral assembly and replication); and NS3/4A protease inhibitors (e.g., glecaprevir, grazoprevir — block HCV polyprotein processing). Modern regimens combine DAAs from two or three classes to prevent resistance.

The two most widely used pangenotypic (effective for all HCV genotypes) regimens currently are:

• Sofosbuvir/velpatasvir (Epclusa): 12 weeks for most patients without cirrhosis; 12 weeks with ribavirin or 24 weeks without ribavirin for genotype 3 with cirrhosis. One tablet once daily.
• Glecaprevir/pibrentasvir (Mavyret/Maviret): 8 weeks for most treatment-naive patients without cirrhosis (including all genotypes); 12 weeks for patients with compensated cirrhosis; 16 weeks for prior treatment failures with certain regimens. Three tablets once daily.

Both regimens are highly effective in treatment-naive patients. Choice between regimens considers factors such as renal function (sofosbuvir requires dose caution in severe renal impairment; glecaprevir/pibrentasvir has no renal dose adjustment), drug interactions (protease inhibitor-containing regimens like glecaprevir have more interactions), and local drug availability and cost.

Treatment eligibility has expanded dramatically in recent years. Current guidelines from AASLD and the European Association for the Study of the Liver (EASL) recommend HCV treatment for all patients with chronic HCV infection who do not have a contraindication, regardless of fibrosis stage — including patients with mild fibrosis (F0–F1) who were historically not prioritised for treatment under resource-constrained programmes. The rationale is that cure prevents long-term progression, eliminates transmission risk, resolves extrahepatic manifestations, and improves quality of life.

Monitoring During and After Treatment

During DAA treatment, clinical monitoring is relatively minimal compared to the intensive monitoring required for interferon-based regimens. Most patients require baseline blood tests, a mid-treatment assessment in selected high-risk patients, and an end-of-treatment viral load check. HCV RNA testing at twelve weeks post-treatment (SVR12) is the primary endpoint that confirms cure.

After confirmed SVR12, the monitoring requirements depend on the fibrosis stage at treatment:

• Patients with F0–F2 fibrosis: Following SVR12, most patients can be discharged from specialist hepatology follow-up. Ongoing monitoring by their GP includes annual liver function tests if any risk factors for recurrence remain, and testing for reinfection in patients who continue to have ongoing HCV exposure risk.
• Patients with F3–F4 fibrosis (advanced fibrosis or cirrhosis): Ongoing surveillance is required even after SVR because the risk of HCC does not return to zero once cirrhosis has developed. Six-monthly ultrasound surveillance for HCC is recommended for all patients with cirrhosis, with or without AFP measurement. Portal hypertension surveillance (including variceal screening endoscopy) is also continued in patients with established cirrhosis.

It is important to understand that reinfection is possible after SVR — HCV does not produce lasting immunity, unlike hepatitis A or B. Patients who achieve SVR but continue to have HCV exposure risk (e.g., people who inject drugs) should be retested for HCV RNA periodically and offered harm reduction support. Reinfection is treatable with a further DAA course.

Special Populations and Considerations

HIV co-infection: Approximately 2.3 million people globally have HIV-HCV co-infection. HIV accelerates HCV fibrosis progression, increasing HCC risk and the severity of liver-related complications. DAA therapy is equally effective in HIV co-infected patients, but drug interactions with antiretroviral therapy require careful consideration — particularly for regimens containing protease inhibitors (glecaprevir in Mavyret interacts with some antiretrovirals) and the efavirenz-based regimens that reduce sofosbuvir/velpatasvir levels. An HIV specialist or hepatologist with HCV experience should review antiretroviral regimens before DAA initiation.

Renal impairment: Sofosbuvir-based regimens require caution in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m², including those on haemodialysis. Glecaprevir/pibrentasvir (Mavyret) is safe in all stages of renal impairment, including dialysis patients, and is generally the preferred regimen in this population.

Decompensated cirrhosis: Patients with decompensated cirrhosis (Child-Pugh B or C, with ascites, variceal bleeding, hepatic encephalopathy, or jaundice) represent a special management challenge. Protease inhibitor-containing regimens (including glecaprevir-based regimens) are contraindicated in decompensated cirrhosis because hepatic metabolism is required and drug accumulation occurs. Sofosbuvir/velpatasvir is the preferred regimen in this population. Patients with decompensated cirrhosis who achieve SVR may experience significant hepatic improvement — in some cases sufficient to be removed from liver transplant waitlists — though a proportion will have irreversible cirrhotic damage and continue to require transplantation.

People who inject drugs: HCV treatment is safe and effective in people who inject drugs (PWID), even in those who are currently using. The concern that PWID will not adhere to treatment or will reinfect immediately has not been borne out by evidence — multiple studies have shown cure rates comparable to the general population in PWID who receive treatment with appropriate support. Integrating HCV treatment with harm reduction programmes (needle and syringe programmes, opioid agonist therapy) improves outcomes and reduces reinfection rates. The WHO and most international guidelines specifically recommend offering treatment to all PWID, not restricting it based on current drug use status.

Frequently Asked Questions

Hepatitis C and the Global Elimination Goal

The WHO has set a target to eliminate HCV as a public health threat by 2030, defined as an 80% reduction in new HCV infections and a 65% reduction in HCV mortality compared to 2015 levels. The DAA cure rate makes this goal biologically achievable in a way that was impossible in the interferon era. The challenge is not therapeutic efficacy — it is diagnosis, linkage to care, and treatment access.

Globally, only around 21% of people with chronic HCV infection had been diagnosed as of the most recent WHO estimates. Even among those diagnosed, a significant proportion do not access treatment due to cost, stigma, healthcare system barriers, or lack of awareness. Elimination will require massive expansion of testing (including point-of-care testing in primary care, pharmacies, and community settings), integration of HCV services with harm reduction and primary care, continued price reductions in DAA medications, and sustained public health awareness efforts.

For individuals, the message is simpler: hepatitis C is tested for with a blood test, treated with an 8–12 week course of tablets, and cured in over 95% of people. If you have any risk factors for HCV or have simply never been tested, a conversation with your GP about HCV screening is one of the most impactful liver health steps available. The comparison with other hepatitis infections makes the opportunity especially clear — HCV is the one for which cure is already here, waiting to be used.

References and Further Reading

This article draws on evidence and guidelines from: World Health Organization — Hepatitis C fact sheet; AASLD/IDSA HCV Guidance Panel — HCV Guidance; EASL Recommendations on Treatment of Hepatitis C; NHS — Hepatitis C; Collaborators GH. Global prevalence and genotype distribution of HCV: a systematic review. Lancet Gastroenterol Hepatol. 2017; Gower E et al. Global epidemiology and genotype distribution of HCV. J Hepatol. 2014;61(1 Suppl):S45–57; Pawlotsky JM et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2016;65(1 Suppl):S139–48.

Sources: WHO, AASLD/IDSA HCV Guidance, EASL, NHS, Lancet Gastroenterology & Hepatology, Journal of Hepatology